Voyager Therapeutics, Inc. (NASDAQ: VYGR) began Monday virtually unchanged The Lexington, Mass.- concern, a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2025 financial results.
Voyager had collaboration revenue of $13.4 million for the third quarter of 2025, compared to $24.6 million for the same period in 2024. General and administrative expenses were $8.1 million for the third quarter of 2025, compared to $8.2 million for the same period in 2024. The consistent spend reflects continued disciplined expense management after the restructuring during the second quarter of 2025.
Net loss was $27.9 million for the third quarter of 2025, compared to $9.0 million for the same period in 2024.
Cash, cash equivalents and marketable securities as of September 30, 2025, were $229 million.
Said CEO Alfred Sandrock, “Voyager continues to seek out the optimal modalities for each neurotherapeutic target we pursue.
“During the third quarter, we shared initial preclinical data on our Voyager NeuroShuttle, a nonviral delivery platform with differentiated pharmacokinetics from transferrin receptor shuttle approaches. We are now introducing our first NeuroShuttle program.”
“Additionally, Voyager entered into a collaboration with Transition Bio in which we will have an option to license Transition Bio’s small molecules for ALS and FTD. TDP-43 appears to play a pivotal role in the pathophysiology of the vast majority of ALS cases, yet has been historically considered undruggable.”
VYGR shares eked up six cents, or 1.4%, to begin Monday at $4.29.
